<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    10714657
   </pmid>
   <datecreated>
    <year>
     2000
    </year>
    <month>
     03
    </month>
    <day>
     23
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2000
    </year>
    <month>
     03
    </month>
    <day>
     23
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2007
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0003-9942
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       57
      </volume>
      <issue>
       3
      </issue>
      <pubdate>
       <year>
        2000
       </year>
       <month>
        Mar
       </month>
      </pubdate>
     </journalissue>
     <title>
      Archives of neurology
     </title>
     <isoabbreviation>
      Arch. Neurol.
     </isoabbreviation>
    </journal>
    <articletitle>
     Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses.
    </articletitle>
    <pagination>
     <medlinepgn>
      326-32
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">
      Aspirin therapy reduces stroke by about 25% for persons with atherosclerotic vascular disease, but the effect in those without clinically apparent vascular disease is distinctly different.
     </abstracttext>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To define the effect of aspirin use on stroke and other major vascular events when given for primary prevention to persons without clinically recognized vascular disease.
     </abstracttext>
     <abstracttext label="DATA SOURCES AND EXTRACTION" nlmcategory="METHODS">
      Systematic review of randomized clinical trials and large prospective observational cohort studies examining the relation between aspirin use and stroke in persons at low intrinsic risk. Studies were identified by a computerized search of the English-language literature.
     </abstracttext>
     <abstracttext label="DATA SYNTHESIS" nlmcategory="RESULTS">
      Five randomized trials of primary prevention included 52 251 participants randomized to aspirin doses ranging from 75 to 650 mg/d; the mean overall stroke rate was 0.3% per year during an average follow-up of 4.6 years. Meta-analysis revealed no significant effect on stroke (relative risk = 1.08; 95% confidence interval, 0.95-1.24) contrasting with a decrease in myocardial infarction (relative risk = 0.74; 95% confidence interval, 0.68-0.82). The lack of reduction of stroke by aspirin for primary prevention was incompatible with its protective effect against stroke in patients with manifest vascular disease (P = .001). Intracranial hemorrhage was increased by the regular use of aspirin (relative risk = 1.35; P = .03), similarly for both primary and secondary prevention. In 4 large observational studies, self-selected use of aspirin was consistently associated with higher rates of stroke.
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      The effect of aspirin therapy on stroke differs between individuals based on the presence or absence of overt vascular disease, in contrast with the consistent reduction in myocardial infarction by aspirin therapy observed in all populations. We hypothesize that the effect of aspirin therapy on stroke for persons with major risk factors for vascular disease may be intermediate between a substantial decrease for those with manifest vascular disease and a possible small increase for healthy persons due to accentuated intracranial hemorrhage. When aspirin is given for primary prevention of vascular events, available data support using 75 to 81 mg/d.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Medicine (Neurology), University of Texas Health Science Center, San Antonio 78284, USA. hartr@uthscsa.edu
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Hart
      </lastname>
      <forename>
       R G
      </forename>
      <initials>
       RG
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Halperin
      </lastname>
      <forename>
       J L
      </forename>
      <initials>
       JL
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       McBride
      </lastname>
      <forename>
       R
      </forename>
      <initials>
       R
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Benavente
      </lastname>
      <forename>
       O
      </forename>
      <initials>
       O
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Man-Son-Hing
      </lastname>
      <forename>
       M
      </forename>
      <initials>
       M
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Kronmal
      </lastname>
      <forename>
       R A
      </forename>
      <initials>
       RA
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Meta-Analysis
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     UNITED STATES
    </country>
    <medlineta>
     Arch Neurol
    </medlineta>
    <nlmuniqueid>
     0372436
    </nlmuniqueid>
    <issnlinking>
     0003-9942
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Platelet Aggregation Inhibitors
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      50-78-2
     </registrynumber>
     <nameofsubstance>
      Aspirin
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Arch Neurol. 2000 Mar;57(3):306-8
     </refsource>
     <pmid version="1">
      10714652
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Arteriosclerosis
     </descriptorname>
     <qualifiername majortopicyn="Y">
      prevention &amp; control
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aspirin
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="N">
      pharmacology
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Intracranial Hemorrhages
     </descriptorname>
     <qualifiername majortopicyn="Y">
      etiology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Platelet Aggregation Inhibitors
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="N">
      pharmacology
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Preventive Medicine
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Risk Factors
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Sex Factors
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Stroke
     </descriptorname>
     <qualifiername majortopicyn="Y">
      prevention &amp; control
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2000
     </year>
     <month>
      3
     </month>
     <day>
      14
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2000
     </year>
     <month>
      3
     </month>
     <day>
      25
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2000
     </year>
     <month>
      3
     </month>
     <day>
      14
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     10714657
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

